Analysts expect bluebird bio Inc (NASDAQ:BLUE) to report sales of $10.33 million for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for bluebird bio’s earnings, with estimates ranging from $5.00 million to $12.00 million. bluebird bio reported sales of $4.17 million in the same quarter last year, which indicates a positive year over year growth rate of 147.7%. The company is expected to report its next earnings report on Wednesday, February 20th.
According to Zacks, analysts expect that bluebird bio will report full-year sales of $44.08 million for the current year, with estimates ranging from $37.00 million to $48.00 million. For the next financial year, analysts expect that the firm will report sales of $72.89 million, with estimates ranging from $55.67 million to $121.59 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow bluebird bio.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.90) by $0.17. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The business had revenue of $11.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the prior year, the company earned ($1.73) EPS. The firm’s quarterly revenue was up 49.2% on a year-over-year basis.
A number of analysts recently commented on BLUE shares. Cantor Fitzgerald set a $122.00 price objective on shares of bluebird bio and gave the company a “sell” rating in a research report on Wednesday, September 5th. ValuEngine upgraded shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Piper Jaffray Companies cut shares of bluebird bio from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $240.00 to $120.00 in a research report on Thursday. Oppenheimer restated a “hold” rating on shares of bluebird bio in a research report on Tuesday, November 27th. Finally, William Blair restated a “buy” rating on shares of bluebird bio in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seventeen have issued a buy rating to the company. bluebird bio presently has a consensus rating of “Buy” and an average price target of $194.80.
In other bluebird bio news, insider David Davidson sold 2,000 shares of the stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $121.05, for a total transaction of $242,100.00. Following the completion of the transaction, the insider now owns 30,905 shares in the company, valued at approximately $3,741,050.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James Mandell sold 1,000 shares of the stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $150.77, for a total value of $150,770.00. Following the transaction, the director now owns 1,568 shares of the company’s stock, valued at approximately $236,407.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,490 shares of company stock valued at $2,901,186. Corporate insiders own 3.00% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Stratos Wealth Partners LTD. bought a new position in bluebird bio during the 3rd quarter worth about $106,000. Belpointe Asset Management LLC acquired a new position in shares of bluebird bio during the 3rd quarter worth about $110,000. NuWave Investment Management LLC boosted its stake in shares of bluebird bio by 10,811.1% during the 3rd quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock worth $143,000 after buying an additional 973 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of bluebird bio by 635.0% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock worth $167,000 after buying an additional 997 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in shares of bluebird bio during the 2nd quarter worth about $201,000.
Shares of BLUE traded down $6.62 during trading hours on Monday, reaching $102.23. The stock had a trading volume of 1,024,569 shares, compared to its average volume of 690,709. bluebird bio has a 52 week low of $100.99 and a 52 week high of $236.17. The stock has a market cap of $5.95 billion, a P/E ratio of -13.26 and a beta of 2.37.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Featured Article: Stop Order
Get a free copy of the Zacks research report on bluebird bio (BLUE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.